Sector
HealthcareOpen
₹131Prev. Close
₹131.41Turnover(Lac.)
₹1,336.23Day's High
₹139.9Day's Low
₹12852 Week's High
₹169.352 Week's Low
₹82.95Book Value
₹37.3Face Value
₹1Mkt Cap (₹ Cr.)
2,807.04P/E
0EPS
0Divi. Yield
016 Jan 2025
12:00 AM
Board Meeting
Agenda : Audited Result
6 May 2024
12:00 AM
BookCloser
6 May 2024
12:00 AM
AGM
Announcement Date: 06 May, 2024
| Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
|---|---|---|---|---|
Equity Capital | 21.81 | 21.81 | 14.54 | 49.65 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 823.57 | 831.64 | 461.44 | 352.01 |
Net Worth | 845.38 | 853.45 | 475.98 | 401.66 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Revenue | 11.84 | 13.47 | 14.41 | 625.25 |
yoy growth (%) | -12.12 | -6.49 | -97.69 | 15.03 |
Raw materials | 0 | 0 | 0 | -153.7 |
As % of sales | 0 | 0 | 0 | 24.58 |
Employee costs | -17.46 | -15.28 | -14.59 | -58.73 |
| Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Profit before tax | -36.24 | -27.95 | -25.93 | 230.26 |
Depreciation | -4.39 | -4.34 | -4.16 | -21.3 |
Tax paid | 0 | 5.32 | 12.18 | -71.83 |
Working capital | -73.46 | 43.42 | -154.2 | 81.51 |
Other operating items |
| Y/e 31 Mar | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | -12.12 | -6.49 | -97.69 | 15.03 |
Op profit growth | 19.95 | -13.37 | -115.13 | 40.86 |
EBIT growth | 31.61 | 6.86 | -110.81 | 42.32 |
Net profit growth | 60.16 | 64.55 | -108.68 | 28.3 |
| Particulars (Rupees in Crores.) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
|---|---|---|---|---|---|
Gross Sales | 11.69 | 13.54 | 11.84 | 13.48 | 14.41 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 11.69 | 13.54 | 11.84 | 13.48 | 14.41 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 28.59 | 14.45 | 5.32 | 7.75 | 14.04 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Max Healthcare Institute Ltd MAXHEALTH | 1,137.65 | 135.18 | 1,10,391.59 | 138.24 | 0.13 | 697.4 | 81.72 |
Apollo Hospitals Enterprise Ltd APOLLOHOSP | 6,714.55 | 80.42 | 96,641.26 | 341.6 | 0.24 | 2,054.8 | 569.62 |
Fortis Healthcare Ltd FORTIS | 649.45 | 243.13 | 49,008.11 | 39.56 | 0.15 | 366.87 | 120.23 |
Narayana Hrudayalaya Ltd NH | 1,677.45 | 79.9 | 34,289.7 | 79.22 | 0.24 | 865.04 | 95.32 |
Global Health Ltd MEDANTA | 1,234.2 | 84.4 | 33,119.51 | 99.31 | 0 | 624.4 | 113.49 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman & CEO
Venkateswarlu Jasti
Whole-time Director
Sudha Rani Jasti
Non Executive Director
Seyed E Hasnain
Independent Director
Santanu Mukherjee
Independent Director
J A S Padmaja
Company Sec. & Compli. Officer
Shrenik Soni
Independent Director
V Sambasiva Rao
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Suven Life Sciences Ltd
Summary
Suven Life Sciences Limited (Formerly known as Suven Pharmaceuticals Ltd) was incorporated in March, 1989. The Company changed its name from Suven Pharmaceuticals Limited to Suven Life Sciences Limited in September, 2003. Promoted by Sudharani Jasti and Venkateswarlu Jasti, the Company began operations in 1989 as specialty chemicals provider.The Company is a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of novel therapeutics for the treatment of neurodegenerative disorders. Suven has a wholly owned subsidiary, Suven Neurosciences, Inc., USA, focused on clinical development activities of Suven molecules from phase 2, Proof-of-Concept (POC) studies.The Company is in the business of Contract Research And Manufacturing Services (CRAMS), catering to the needs of global life science industry and fine chemical majors. Suvens CRAMS provide innovative process research and development, supplies to clinical trials, rapid response pilot scale manufacture, dedicated commercial manufacturing on an exclusive basis. The services include Custom Synthesis, Process R&D, Scale Up and Contract Manufacturing of intermediates, APIs and formulations. Suven Life Sciences has graduated from contract research to Collaborative Research transitioning from project-based transactions into relationship-based business.In March 1995, SPL came out with a public issue of 9.8 lac equity shares at a premium of Rs 40 aggregating Rs 4.9 cr to part-finance the
Read More
What is the Suven Life Sciences Ltd share price today?
The Suven Life Sciences Ltd shares price on NATIONAL STOCK EXCHANGE (NSE) is ₹128.72 today.
What is the Market Cap of Suven Life Sciences Ltd?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Suven Life Sciences Ltd is ₹2807.04 Cr. as of 04 Apr ‘25
What is the PE and PB ratio of Suven Life Sciences Ltd?
The PE and PB ratios of Suven Life Sciences Ltd is 0 and 3.46 as of 04 Apr ‘25
What is the 52 Week High and Low of Suven Life Sciences Ltd?
The 52-week high/low is the highest and lowest price at which a Suven Life Sciences Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Suven Life Sciences Ltd is ₹82.95 and ₹169.3 as of 04 Apr ‘25
What is the CAGR of Suven Life Sciences Ltd?
Suven Life Sciences Ltd's CAGR for 5 Years at 46.21%, 3 Years at 13.52%, 1 Year at 23.16%, 6 Month at -7.35%, 3 Month at 1.96% and 1 Month at 22.57%.
What is the shareholding pattern of Suven Life Sciences Ltd?
The shareholding pattern of Suven Life Sciences Ltd is as follows:
Promoters - 70.27 %
Institutions - 1.39 %
Public - 28.34 %
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
